On November 7th, the Information Office of the Guangzhou Municipal People's Government held a press conference on the 3rd Guangdong Hong Kong Macao Greater Bay Area Health Cooperation Conference. At the meeting, Mou Zhiping, Executive Deputy Director of the Dawan District Office and Deputy Director of the Municipal Development and Reform Commission of Guangzhou, introduced the development situation and future development plans of the biopharmaceutical industry in Guangzhou.

Mou Zhiping introduced that in recent years, the Guangzhou Municipal Party Committee and Government have deeply implemented the "Outline of the Development Plan for the Guangdong Hong Kong Macao Greater Bay Area", attached great importance to the development of strategic emerging biopharmaceutical industries, and vigorously promoted the integration, clustering, and ecological development of industries. The industrial cluster has been awarded incentives and commendations by the State Council for three consecutive years from 2018 to 2020, and was awarded excellent in the first batch of national strategic emerging industrial cluster evaluations in 2023, Ranked among the top tier of the country in terms of development level.

Mou Zhiping believes that the high-quality development of Guangzhou's biopharmaceutical industry has made significant progress in the following three aspects. Firstly, the scale of industrial development continues to grow. In 2022, the added value of the biopharmaceutical and health industry in Guangzhou was 1651.47 billion yuan, accounting for 5.73% of GDP, a year-on-year increase of 8.5%; In the first three quarters of this year, the added value reached 124.82 billion yuan. There are currently over 6400 biopharmaceutical companies of various types, including 12 Fortune Global 500 companies, 139 above designated enterprises, and 54 listed companies. The second is the continuous improvement of the industrial policy system. In recent years, a series of policy measures have been introduced, including the "Several Provisions on Accelerating the Development of the Biomedical Industry in Guangzhou (Revised)" and the "Implementation Plan for Accelerating the Development of the Medical Testing Industry Cluster in Guangzhou", to support Guangzhou's formation of certain advantages in the sub fields of antibody drugs, nucleic acid drugs, modern Chinese medicine, high-end medical devices, gene editing, and stem cell therapy. The third is the continuous enhancement of industrial innovation capabilities. The construction of strategic scientific and technological forces such as Guangzhou Laboratory, Human Cell Genealogy Science Facility, and Human Proteome Navigation International Science Program is accelerating, all located in the International Biological Island Park. There are currently 217 innovation related platforms in the biopharmaceutical industry. In the first three quarters of this year, the city has obtained 81 new drug approvals, of which 60 are Class I new drugs. Form a multi-level talent pool led by Nobel laureates, academicians of the Chinese Academy of Sciences and Chinese Academy of Engineering, and industry leaders.

Looking ahead to the future, Mou Zhiping stated that in the next step, Guangzhou will base itself on the Bay Area, face the world, focus on major regions, key areas, and key links, highlight reform leadership, innovation leadership, and openness leadership, adhere to strengthening top-level design, innovation leadership breakthroughs, innovation resource aggregation, building industrial ecology, and high-level opening up to the outside world. Guangzhou will coordinate the planning and layout of industrial parks throughout the city, and coordinate policy resources throughout the city, Continuously deepening cooperation between Hong Kong and Macao, vigorously promoting the innovative development, agglomeration development, ecological development, and international development of Guangzhou's biopharmaceutical industry, and striving to create a global highland for biopharmaceutical innovation and industrial development. One is to accelerate the research and formulation of the "1+N" policy system. We are researching and formulating several policy measures to promote the high-quality development of the biopharmaceutical industry in Guangzhou. We are currently publicly soliciting opinions on the official website. Friends from all walks of life are requested to continue to pay attention and provide valuable opinions. We will accelerate the necessary procedures, issue and implement them as soon as possible, and enable enterprises to benefit as soon as possible. At the same time, we will accelerate the research and development of special implementation plans for research-oriented hospitals, major innovative pharmaceutical product catalogs, and other specific matters, and construct N supporting measures. The second is to systematically plan the "one island, multiple parks" park planning. Focus on optimizing and enhancing the core spatial layout of the International Biological Island, creating a pilot zone for the "one island, multiple parks" policy with the International Biological Island as the park brand, and creating the latest landmark industrial cluster in the city. The third is to further improve the industrial development ecosystem. Actively host the 16th China Bioindustry Conference in 2024. Support influential leading enterprises to lead the formation of innovation consortia, accelerate the research and development, industrialization, and clinical application iteration of innovative drugs and high-end medical devices.